The grades of seven pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
NuPathe Inc. (PATH) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. NuPathe develops pharmaceutical products used for the treatment and management of neurological and psychiatric diseases. In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, PATH also gets A’s. For more information, get Portfolio Grader’s complete analysis of PATH stock.
GW Pharmaceuticals PLC Sponsored ADR’s (GWPH) ratings are looking better this week, moving up to a B from last week’s C. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of GWPH stock.
Watson Pharmaceuticals (WPI) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
Paratek Pharmaceuticals Inc (PRTK) gets a higher grade this week, advancing from a B last week to an A. For more information, get Portfolio Grader’s complete analysis of PRTK stock.
Cardiome Pharma (CRME) improves from a C to a B rating this week. Cardiome Pharma focuses on the discovery, development, and commercialization of drugs to treat or prevent cardiovascular and other diseases. For more information, get Portfolio Grader’s complete analysis of CRME stock.
AbbVie, Inc. (ABBV) boosts its rating from a C to a B this week. AbbVie, a research-based biopharmaceutical company, engages in the discovery, development, manufacture, and sale of pharmaceutical products worldwide. For more information, get Portfolio Grader’s complete analysis of ABBV stock.
Agile Therapeutics, Inc. (AGRX) is seeing ratings go up from a C last week to a B this week. For more information, get Portfolio Grader’s complete analysis of AGRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
